European authorisation for schizophrenia drug

Monday 2nd July 2007

The European Commission has granted marketing authorisation for the atypical antipsychotic Invega™ (paliperidone) for the treatment of schizophrenia. This once-daily medication, which uses the OROS® osmotic delivery system to deliver paliperidone in a prolonged release manner, will be marketed in Europe by Janssen-Cilag.

The EU approval of Invega is based on efficacy and safety results of an extensive clinical development programme. The recommended dose of Invega is 6mg/day, with a dose range of 3–12mg/day depending on patient need.

National Electronic Library for Medicines 29/6/2007